Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 3,17 € (+296,25 %). Medianen er 3,17 € (+296,25 %).

Køb	12
Behold	0
Sælg	0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Stereotaxis acquires Robocath and integrates robotic cardiology technology

Stereotaxis has completed the acquisition of Robocath and is integrating its team and the R-One robotic system, which is CE- and NMPA-certified and used in Europe and China. Clinical studies report a technical success rate of over 98% without major cardiovascular events. The transaction includes contingent payments tied to regulatory and commercial milestones; financial details were not disclosed. Stereotaxis most recently reported annual revenue of USD 31.2 million while remaining unprofitable; market capitalization is USD 175.93 million, analyst targets range from USD 3.50 to 5.00, while the current share price is around USD 1.80. » Mere på de.investing.com
Stereotaxis elects three directors and confirms EY as independent auditor

At Stereotaxis’s annual general meeting, David Benfer, Dr. Arun Menawat and Dr. Myriam Curet were elected to the board through 2029, Ernst & Young was confirmed as the independent auditor for 2026, and executive compensation was approved in an advisory vote. The meeting was quorate with about 65.3% of the voting capital. Separately, Stereotaxis reported Q1 2026 results that missed market expectations (EPS -$0.06; revenue $6.3 million), triggering a share price decline. » Mere på de.investing.com
Stereotaxis misses Q1 forecasts; shares fall in after-hours

Stereotaxis reported Q1 2026 EPS of -$0.06 (forecast -$0.05) and revenue of $6.3m versus expected $8.72m. Revenue fell 15.9% year‑on‑year, weighed down by the strategic move away from Johnson & Johnson’s catheter ecosystem and production bottlenecks for new products. Management points to important regulatory approvals and plans to ramp production to 500 MAGiC catheters per month by the end of 2026, but expects continued short‑term revenue volatility. The stock fell about 3.7% after the results to $1.81 and is approaching its 52‑week low. » Mere på de.investing.com
Stereotaxis opens the books for the quarter; analysts expect smaller loss and revenue growth

Stereotaxis will open the books for the quarter ending 31.12.2025 on 09.03.2026. Four analysts on average forecast EPS of -0.063 USD versus -0.090 USD a year ago. Five analysts expect revenue to rise 43.22% to 9.1 Mio. USD (prior year 6.3 Mio. USD). For the fiscal year, analysts see an average loss per share of -0.255 USD and revenue of 32.8 Mio. USD versus 26.9 Mio. in the prior year. » Mere på finanzen.net
Stereotaxis rises sharply after FDA approval for robotic MAGiC ablation catheter

Stereotaxis’s stock jumped 8.3% after the announcement of FDA approval for the interventional magnetic ablation catheter MAGiC. The catheter enables precise, computer-controlled magnetic navigation for cardiac ablation procedures and is indicated for electrophysiological mapping, delivery of diagnostic stimulations, and endocardial lesions. Stereotaxis sees the approval as a milestone toward expanding access to ablation therapy for complex and previously underserved patient groups. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Stereotaxis en omsætning på 7,88 mio. € og et nettoresultat på -5,72 mio. €

(EUR)	september 2026	YoY
Omsætning	7,88 mio.	23,88 %
Bruttofortjeneste	3,49 mio.	0,06 %
Nettoresultat	-5,72 mio.	3,91 %
EBITDA	-5,68 mio.	9,81 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	93,35 mio. €
Antal aktier	100,2 mio.
Højeste/laveste i 52 uger	2,61 € - 0,72 €
Udbytte	Nej
Beta	1,40
P/E (PE Ratio)	-4,23
PEG (PEG Ratio)	-0,29
K/I (PB Ratio)	4,94
P/S (PS Ratio)	3,27

Virksomhedsprofil

Stereotaxis, Inc. designer, fremstiller og markedsfører robotsystemer, instrumenter og informationssystemer til det interventionelle laboratorium i USA og internationalt. Dets robotbaserede magnetiske navigationssystemer (RMN) omfatter Genesis RMN- og Niobe-systemerne, som gør det muligt for læger at gennemføre komplekse interventionelle procedurer ved at levere katetre og guidewires gennem blodkar og hjerkamre til behandlingssteder under billedvejledning. Virksomheden tilbyder også Odyssey, en realtidsinformationsløsning til at administrere, styre, optage og dele procedurer på tværs af netværk; og Stereotaxis Imaging Model S X-ray-system, et enkeltplans røntgensystem med fuld effekt, herunder c-arm, drevet bord, motoriseret arm og store højopløselige skærme til en robotbaseret interventionel operationsstue. Derudover tilbyder den engangsartikler og andet tilbehør, såsom QuikCAS automatiske kateterfremføringsengangsartikler til fjernfremføring af elektrofysiologiske katetre; samt CARTO RMT navigations- og ablationssystemet, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL og CELSIUS RMT THERMOCOOL irrigerede spidsdiagnostiske/ablationsstyrbare spidskatetre. Endvidere tilbyder virksomheden Vdrive, et system der giver navigation og stabilitet til diagnostiske og terapeutiske enheder designet til at forbedre interventionelle procedurer; og V-Loop, V-Sono og V-CAS engangskomponenter. Stereotaxis, Inc. markedsfører sine produkter gennem direkte salgsstyrke, distributører og salgsagenter. Virksomheden har et strategisk samarbejde med Osypka AG om at udvikle et magnetisk ablationskateter ved hjælp af Stereotaxis' robotteknologi. Stereotaxis, Inc. blev stiftet i 1990 og har hovedsæde i Saint Louis, Missouri.

Navn	Stereotaxis
CEO	David L. Fischel
Hjemsted	St. Louis, mo USA
Websted	stereotaxis.com
Sektor	Sundhed
Branche	Sundhedsudstyr og -produkter
Børsnotering	12.08.2004
Medarbejdere	131